Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder ('GAD').
The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004.
'Patents are extremely valuable assets, and protection for our lead product candidates is a top priority for us,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We believe that our CYB004 program has the potential to deliver short-duration, rapid-acting treatment for anxiety disorders and offer more patient-friendly dosing methods such as IM administration. The issuance of this additional patent in support of CYB004 adds further validation of this important program. Dosing is currently underway in our Phase 2 study evaluating CYB004 in generalized anxiety disorder, and we expect the study to complete around mid-year. I'm proud that Cybin has amassed one of the strongest IP portfolios in the sector with more than 90 granted patents and over 230 pending applications.'
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; plans to complete the Phase 2 GAD study around mid-year 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations.
Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
FTRE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Fortrea Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP Fortrea class action lawsuit. Captioned Deslande v. Fortrea Holdings Inc., No. 25-cv-04630 (S.D.N.Y.), the Fortrea class action lawsuit charges Fortrea and certain of Fortrea's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Fortrea class action lawsuit, please provide your information here: CASE ALLEGATIONS: Fortrea is a global clinical research organization ('CRO') that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. According to the complaint, in June 2023, Labcorp Holdings Inc. spun off Fortrea as a standalone, publicly traded company (the 'Spin-Off'). At the time of the Spin-Off, certain of the long-term projects in Fortrea's portfolio remained ongoing (the 'Pre-Spin Projects'). In connection with the Spin-Off, Labcorp and Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which Fortrea pays Labcorp to provide certain transitional services for a set period. The Fortrea class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to Fortrea's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, Fortrea's previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of Fortrea's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated. The Fortrea class action lawsuit further alleges that on September 25, 2024, Jefferies published a report downgrading Fortrea from buy to hold, citing perceived weaknesses in Fortrea's business model as a CRO amid pressure on biotechnology funding and suggested that the cost savings Fortrea expects to achieve by exiting the TSAs are '[n]ot as [m]aterial as [o]ne [m]ight [t]hink,' stating that 'IT infrastructure costs to exit the TSAs are already non-GAAPed out of adjusted EBITDA. Thus, once TSAs are exited, [Fortrea] will just be replacing TSA costs with internal operating costs.' On this news, the price of Fortrea stock fell more than 12%, according to the complaint. Then, on December 6, 2024, market analyst Baird Equity Research downgraded Fortrea to neutral from outperform after Fortrea abruptly cancelled two scheduled conferences, stating that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell),' according to the complaint. The Fortrea class action lawsuit alleges that on this news, the price of Fortrea stock fell more than 8%. Finally, on March 3, 2025, the Fortrea class action lawsuit further alleges that Fortrea announced its fourth quarter and full year 2024 financial results, disclosing that its 'targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.' According to the complaint, specifically, in an earnings call held that same day, Fortrea revealed that Fortrea's Pre-Spin projects are 'late in their life cycle [and] have less revenue and less profitability than expected for 2025,' that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics,' and that 'older versus newer mix issue will continue to negatively impact [Fortrea's] financial performance during 2025.' On this news, the price of Fortrea stock fell more than 25%, according to the Fortrea class action lawsuit. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Fortrea securities during the Class Period to seek appointment as lead plaintiff in the Fortrea class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Fortrea class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Fortrea class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Fortrea class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Yahoo
36 minutes ago
- Yahoo
IDEX Biometrics ASA: Final result of the Subsequent Offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange notice from IDEX Biometrics ASA (the "Company") on 21 May 2025 regarding the commencement of the subscription period (the "Subscription Period") in the subsequent offering (the "Subsequent Offering") consisting of up to 600,000,000 new shares (the "Offer Shares") in the Company at a subscription price of NOK 0.01 per share ("Offer Price"). The Subscription Period commenced on 22 May 2025 and expired on 5 June 2025. By the end of the Subscription Period, the Subsequent Offering was 8x oversubscribed. Pursuant to the resolution by the Extraordinary General Meeting dated 11 April 2025, the Company's board of directors has today resolved to allocate and issue a total of 600,000,000 Offer Shares at the Offer Price in accordance with the allocation criteria set out in the prospectus dated 21 May 2025, raising gross proceeds of NOK 6 million. Investors that are allocated Offer Shares can access information on the number of Offer Shares allocated to them through VPS on or about 6 June 2025. The due date for payment of the Offer Shares is on 11 June 2025. Subject to duly and timely payment of the Offer Shares, the share capital increase pertaining to the Subsequent Offering is expected to be registered in the Norwegian Register of Business Enterprises ('NRBE') on or about 13 June 2025. Following registration of the share capital increase associated with the Subsequent Offering in the NRBE, the Company's share capital will be NOK 44,316,309.99 consisting of 4,431,630,999 shares, each having a par value of NOK 0.01. The Offer Shares will be delivered to the VPS accounts of the subscribers shortly thereafter, expected on or about 13 June 2025. A separate announcement will be made when the share capital increase has been registered. The Offer Shares will have equal rights and rank pari passu with the Company's other shares. Arctic Securities AS is acting as manager in connection with the Subsequent Offering (the "Manager"). Ræder Bing advokatfirma AS is acting as the Company's legal advisor. For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@ IMPORTANT NOTICE This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The "Prospectus Regulation" means Regulation (EU) 2017/1129, as amended (together with any applicable implementing measures) in any Member State. This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. The issue, subscription or purchase of shares in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Managers assume any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believe that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond their control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation as implemented in any Member State. About IDEX Biometrics: IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit About this notice: This notice was issued by Kristian Flaten, CFO, on 6 June 2025 at 17:20 CET on behalf of IDEX Biometrics ASA. The information is published in accordance with section 5-8 of the Norwegian Securities Trading Act (STA) and released in accordance with section 5-12 of the in to access your portfolio
Business Wire
an hour ago
- Business Wire
American Water Encourages Customers to Prepare for Hurricane Season
BUSINESS WIRE)--American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., provides tips for customers and the general public to help prepare for hurricane season. Whether in the path of a hurricane or facing lesser storms, it is important to be aware of and prepare for extreme weather events. 'Effective storm preparedness is achieved through long-term planning and execution of a capital investment strategy, rather than reacting to forecasts or conditions during the storm itself," said Cheryl Norton, EVP & COO, American Water. 'American Water is committed to taking proactive steps to help ensure our drinking water and wastewater systems remain resilient and our teams are ready to respond quickly and safely to weather-related events,' said Cheryl Norton, EVP and Chief Operating Officer, American Water. 'We encourage our customers to prepare as well by taking simple steps like storing emergency water supplies and staying informed.' In the event of a hurricane or extreme weather incident, American Water advises customers to take the following precautions ahead of time, including: Conserving water for essential needs; Filling your bathtub and other watertight containers with water in advance of the storm's arrival should water service be disrupted; If you are asked to evacuate or if you decide to evacuate, consider closing your home's main water shut off valve; Creating an emergency plan to keep everyone in your household on the same page if disaster strikes; and Tracking the latest weather updates—protect yourself and your loved ones and equip your home to best battle this season's storms. As the country continues to face more extreme weather events, American Water recognizes the need to continue investing in critical water infrastructure. Over the next 10 years, American Water plans to invest $40–$42 billion in capital improvements to its systems, largely for pipe replacement and upgrading aging water and wastewater treatment facilities. Capital investments, in parallel with continuous improvement, diligent cost management, and technology enhancements, help the company continue to maximize efficiency while serving customers' needs. 'Effective storm preparedness is achieved through long-term planning and execution of a capital investment strategy, rather than reacting to forecasts or conditions during the storm itself. American Water continues to invest significantly in resiliency projects to address the impacts of climate variability by hardening its assets. Consistent, proactive investment into our systems builds resiliency and sustainability of operations year-round including during extreme weather events,' said Norton. One example is the $37 million flood protection project at the Raritan-Millstone Plant, the largest facility in New Jersey's American Water system, which supplies water to more than one million people across seven counties, to strengthen the plant's resilience against severe weather events. The value of this investment was demonstrated during Tropical Storm Ida , when the newly constructed wall kept the facility dry and fully operational when the areas outside the treatment plant were flooded. Another example is the Pennsylvania American Water Lake Scranton Dams. The Labyrinth Spillways were retrofitted into existing dams to extend the flow area and prevent a spillway failure during high rain. This type of capital improvement significantly mitigates risk to the dam structure as more frequent and intense weather events occur. Investing in water and wastewater infrastructure resilience now is important to address the convergence of factors of water insecurity, aging infrastructure and climate variability. Visit for more tips and information on severe weather preparation. Additionally, the American Water Charitable Foundation, a philanthropic non-profit organization established by American Water, recently announced that it has again donated $250,000 to the American Red Cross, continuing its membership in the Disaster Responder Program. Proactively funding disaster relief helps ensure the Red Cross is better prepared to meet the needs of those affected by disasters, both big and small, across the U.S. About American Water American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.
